Safety Profile of Ozempic (Semaglutide)

Important Disclaimer: This information is for educational purposes only and should not replace consultation with a healthcare provider. Always discuss potential risks and benefits with your doctor before starting or stopping any medication.

Evidence Limitations

The provided evidence base for semaglutide's safety profile is limited, consisting primarily of study titles and abstracts from recent research. More comprehensive safety data would typically come from detailed clinical trial results, regulatory documents, and systematic reviews. The safety information presented here should be considered preliminary based on available evidence.

Known Side Effects

Based on the available evidence, specific side effects are not detailed in the provided abstracts. However, one study mentions "experienced effects" of semaglutide for weight management in a Danish community pharmacy survey, suggesting that real-world users do experience various effects, though the nature of these effects is not specified in the available information.

A pharmacovigilance study using the FAERS (FDA Adverse Event Reporting System) database was identified, but only for tirzepatide (a related GLP-1 receptor agonist), not specifically for semaglutide. This suggests that post-market surveillance studies are being conducted for this class of medications, but the specific findings are not available in the provided evidence.

Drug Interactions

One clinical trial (NCT05671653) was designed to evaluate semaglutide's effects on blood levels of:

Common birth control pills
Omeprazole (a proton pump inhibitor)
Midazolam (a benzodiazepine)

However, this Phase 1 study was terminated, and the results are not available. This suggests potential concerns about drug interactions exist, but definitive data is lacking from the provided evidence.

Special Populations and Contraindications

Fertility and Reproductive Health: One study specifically examines "GLP-1 Receptor Agonists and Fertility," indicating that reproductive effects are an area of investigation for this medication class. However, specific findings are not detailed in the available evidence.

Pregnancy and Birth Control: The terminated drug interaction study's focus on birth control pills suggests potential concerns about contraceptive efficacy when used with semaglutide, though specific data is not provided.

Populations Under Investigation

The available evidence shows semaglutide is being studied in several specific populations, though safety outcomes are not detailed:

People with methamphetamine use disorder (Phase 2 trial)
Patients with idiopathic intracranial hypertension (Phase 3 trial)
People with alcohol use concerns (completed Phase 2 trial)

Real-World Safety Monitoring

Evidence indicates that real-world safety studies are being conducted, including:

A multicentre study from Pakistan examining effectiveness and safety
Community pharmacy-based surveys tracking user experiences
Post-market pharmacovigilance studies

However, specific safety findings from these studies are not available in the provided evidence.

Critical Evidence Gaps

The provided evidence lacks comprehensive details about:

Specific adverse event rates
Severity classifications of side effects
Long-term safety data
Detailed contraindication lists
Complete drug interaction profiles
Safety in special populations (elderly, pediatric, pregnant/nursing)

Clinical Recommendation: Given the limited safety information available in the provided evidence, healthcare providers and patients should consult comprehensive prescribing information, FDA labeling, and current clinical guidelines for complete safety data before making treatment decisions.

Ozempic